Piramal Pharma Limited Completes Acquisition of Majority Stake in Yapan Bio Private Limited

Piramal Pharma Limited has completed its acquisition of a majority stake in Yapan Bio Private Limited, a biopharmaceutical company focused on process development and manufacturing services for clinical trials.

The transaction grants Piramal Pharma majority ownership of Yapan Bio, which provides Good Manufacturing Practice (GMP) compliant manufacturing services for Phase I and II clinical studies. The company specializes in vaccines and biologics.

Piramal Pharma has held a stake in Yapan Bio since 2021. This acquisition expands Piramal's offering in biologics manufacturing capacity, complementing its existing drug product services.

Yapan Bio offers services for the development of both generic and novel biologics, including protein, peptide, heparin, and polysaccharide-based products. The company aims to support clients from early-stage product development through to commercial manufacturing.